Cerebral malaria (CM), a severe neurological pathology caused by Plasmodium falciparum infection, poses a significant global health threat and has a high mortality rate. Conventional therapeutics cannot cross the blood–brain barrier (BBB) efficiently. Therefore, finding effective treatments remains challenging. The novelty of the treatment proposed in this study lies in the feasibility of intranasal (IN) delivery of the nanostructured lipid carrier system (NLC) combining microRNA (miRNA) and artemether (ARM) to enhance bioavailability and brain targeting. The rational use of NLCs and RNA-targeted therapeutics could revolutionize the treatment strategies for CM management. This study can potentially address the challenges in treating CM, allowing drugs to pass through the BBB. The NLC formulation was developed by a hot-melt homogenization process utilizing 3% (w/w) precirol and 1.5% (w/v) labrasol, resulting in particles with a size of 94.39 nm. This indicates an effective delivery to the brain via IN administration. The results further suggest the effective intracellular delivery of encapsulated miRNAs in the NLCs. Investigations with an experimental cerebral malaria mouse model showed a reduction in parasitaemia, preservation of BBB integrity, and reduced cerebral haemorrhages with the ARM+ miRNA-NLC treatment. Additionally, molecular discoveries revealed that nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) and Interleukin-6 (IL-6) levels were reduced in the treated groups in comparison to the CM group. These results support the use of nanocarriers for IN administration, offering a viable method for mitigating CM through the increased bioavailability of therapeutics. Our findings have far-reaching implications for future research and personalized therapy.

Chirality seems to be a pivotal technique in the field of science. Research teams are quite well versed in empirical separation, however, at the same time, they are clueless about the evolution of chiral separation. As per the guidelines of the United States Food and Drug Administration (US FDA), chiral drugs must be untangled before they are sold to the public. Stereogenic separation has gained prominence during the last 10 decades due to the disparate biological function of enantiomers in the stereogenic environment. Chiral drugs exhibit a wide range of bioavailability, distribution, and pharmacodynamic properties concomitantly they exert divergent pharmacological and toxicological properties. Enantiomeric chiral products could be considered safe and potent in combating various diseases including metabolic diseases like diabetes. Several studies have delineated the development of a novel analytical and bioanalytical method to detect/segregate/quantify chiral chemical components in medicinal chemistry. The same physicochemical characteristics of enantiomers have been proven to be beneficial to the estrangement of stereogenic compounds. Furthermore, the advancement of bioanalytical methods is also critical to shedding light on the destiny of distinct enantiomers in the biological environment. HPLC (High-Performance Liquid Chromatography) and CE (Capillary Electrophoresis) have been the most commonly employed separation techniques. But the technical advances are required to enhance the efficiency of detection and quantification of chiral molecules on a large scale. The current review delineates the need for the chiral separation of stereogenic antidiabetic drug compounds with technical advances. Furthermore, this research is focused on the enantioseparation of chiral antidiabetic drugs and a brief overview of the analytical and bioanalytical methods conducted on distant chiral antidiabetic drugs to improve the efficiency of chiral separation.

Background: A chiral HPLC technique was developed to determine sitagliptin phosphate enantiomers in rat plasma in compliance with US FDA regulations. Methods & results: The technique used a Phenome... Tweetable abstract A comprehensive bioanalytical method development and validation of sitagliptin phosphate enantiomers: in vitro evaluation using 3T3-L1 cell lines by flow cytometry and pharmacoki...

Pioglitazone, a PPAR-gamma activator used to diagnose hyperglycemia, was studied for its stereoselective deposition and active enantiomers in female albino Wistar rats. In accordance with USFDA recommendations, a bioanalytical technique was employed to assess the segregation of pioglitazone enantiomers in rat plasma with glimepiride as an internal standard. A Phenomenox i-Amylose-3 column (150 mm × 4.6 mm) of 5 µm was used for high-performance liquid chromatography (HPLC) with a mobile phase of 10 mM ammonium acetate buffer in Millipore water and acetonitrile in 60:40 (v/v) admixture with column temperature 35 °C, wavelength 265 nm, and flow rate 0.6 mL/min, respectively. Pioglitazone-S, Pioglitazone-R, and the internal standard had retention times of 3.1, 7.4, and 1.7 min, respectively. The study found that within-run and between-run precision ranged from 0.1606–0.9889% for Pioglitazone-R and from 0.2080–0.7919% for Pioglitazone-S, while the accuracy ranged from 99.86 to 100.36% for Pioglitazone-R and 99.84 to 99.94% for Pioglitazone-S. In addition, a non-radioactive glucose uptake assay was employed to examine the enantiomers in 3T3-L1 cell lines by flow cytometry. Significant differences were demonstrated in Cmax, AUClast (h*μg/mL), AUCINF obs (h*μg/mL), and AUC%Extrap obs (%) of Pioglitazone-R and S in female albino Wistar rats, suggesting enantioselectivity of pioglitazone.